title: Effects of FGF2 and FGF9 on osteogenic differentiation of bone marrow-derived progenitors.
abstract: Bone repair is a major concern in reconstructive surgery. Transplants containing osteogenically committed mesenchymal stem cells (MSCs) provide an alternative source to the currently used autologous bone transplants which have limited supply and require additional surgery to the patient. A major drawback, however is the lack of a critical mass of cells needed for successful transplantation. The purpose of the present study was to test the effects of FGF2 and FGF9 on expansion and differentiation of MSCs in order to establish an optimal culture protocol resulting in sufficient committed osteogenic cells required for successful in vivo transplantation. Bone marrow-derived MSCs cultured in αMEM medium supplemented with osteogenic supplements for up to three passages (control medium), were additionally treated with FGF2 and FGF9 in various combinations. Cultures were evaluated for viability, calcium deposition and in vivo osteogenic capacity by testing subcutaneous transplants in nude mice. FGF2 had a positive effect on the proliferative capacity of cultured MSCs compared to FGF9 and control medium treated cultures. Cultures treated with FGF2 followed by FGF9 showed an increased amount of extracted Alizarin red indicating greater osteogenic differentiation. Moreover, the osteogenic capacity of cultured cells transplanted in immunodeficient mice revealed that cells that were subjected to treatment with FGF2 in the first two passages and subsequently to FGF9 in the last passage only, were more successful in forming new bone. It is concluded that the protocol using FGF2 prior to FGF9 is beneficial to cell expansion and commitment, resulting in higher in vivo bone formation for successful bone tissue engineering.
authors.affiliation: Department of Anatomy and Cell Biology, Faculty of Medicine, Technion-I.I.T, Haifa 32000, Israel.
authors.forename: T
authors.initials: T
authors.lastname: Kizhner
authors.forename: D
authors.initials: D
authors.lastname: Ben-David
authors.forename: E
authors.initials: E
authors.lastname: Rom
authors.forename: A
authors.initials: A
authors.lastname: Yayon
authors.forename: E
authors.initials: E
authors.lastname: Livne
mesh_terms: D000818:Animals; D000880:Anthraquinones; D001854:Bone Marrow Cells / Q000502:physiology*; D001861:Bone Regeneration / Q000502:physiology*; D018929:Cell Culture Techniques / Q000379:methods; D002454:Cell Differentiation / Q000502:physiology*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D051525:Fibroblast Growth Factor 9 / Q000494:pharmacology*; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D051379:Mice; D008819:Mice, Nude; D009930:Organic Chemicals
chemical_list: D000880:Anthraquinones; C496460:Fgf9 protein, mouse; D051525:Fibroblast Growth Factor 9; D009930:Organic Chemicals; C420642:alpha minimal essential medium; D016222:Fibroblast Growth Factor 2; C010078:alizarin